ANTX missed EPS expectations by 38.15%
Nov 16, 2025, 11:39 AM
0.00%
What does ANTX do
AN2 Therapeutics, a biopharmaceutical company based in Menlo Park, California, focuses on developing treatments for serious infectious diseases, with epetraborole as a potential oral treatment for non-tuberculous mycobacterial lung disease. The company went public on March 25, 2022, and employs 41 people.
AN2 Therapeutics (ANTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, AN2 Therapeutics's actual EPS was -$0.31, missing the estimate of -$0.22 per share, resulting in a -38.15% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.